Design of novel hydrazide–hydrazone derivatives targeting MGC803 gastric cancer cell line by integrating 3D-QSAR, ADMET, network pharmacology, docking, MD simulations and biological efficacy

Abstract The MGC803 cell line is a human gastric cancer model frequently used in cancer research. In this context, a combined in silico approach including 3D-QSAR modeling, ADMET analysis, network pharmacology, docking, molecular dynamics and ligand transport evaluations, was applied to design new antiproliferative molecules. A robust 3D-QSAR model with high predictive capacity ( R² and Q² ) was developed and used to design new compounds (PR1–PR4). After an ADMET screening, the putative biological targets of the non-toxic compounds were predicted using PharmMapper. A network pharmacology analysis identified several hub genes, of which HSP90AA1 had the highest degree value. Given its central role in stabilizing multiple oncogenic proteins involved in gastric cancer progression, as well as its suitability for structure-based studies, HSP90AA1 was selected for molecular docking and molecular dynamics simulations. In addition, molecular docking was performed on HSP90AA1 protein (1YET) in complex with the designed molecules (PR1-PR4), and their predicted binding behaviors were compared to both the most active molecule (M34) and the reference drug, geldanamycin. These results demonstrate a high predicted binding affinity and remarkable interaction profiles within the active site of the HSP90AA1. To further evaluate the dynamic stability of these complexes, we performed molecular dynamics simulations over a 100 ns period, thus confirming stable attachment modes and durable contact networks. The MM-PBSA approach demonstrated favorable binding free energies between the chosen PR4 ligand and the 1YET protein (-26.47 ± 2.89 kcal/mol). Finally, the ligand transport study showed that the PR4 ligand easily crosses tunnels 1 and 2 with optimal theoretical transport dynamics compared to the reference drug, geldanamycin (GA). This comprehensive computational method underlines the diverse potential of the examined molecules, identifying the most promising candidates for subsequent experimental validation against gastric cancer.

Authors

Institutions

Publication Details

Journal
Beni-Suef University Journal of Basic and Applied Sciences
Published
2026-09-01
DOI
https://doi.org/10.1186/s43088-026-00816-0
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Design of novel hydrazide–hydrazone derivatives targeting MGC803 gastric cancer cell line by integrating 3D-QSAR, ADMET, network pharmacology, docking, MD simulations and biological efficacy

Fouad Khalil, Abdellah El Aissouq, Lhoucine Naanaai, Hicham Zaitan et al.
Beni-Suef University Journal of Basic and Applied Sciences
Computational Drug Discovery Methods
article

Design of novel hydrazide–hydrazone derivatives targeting MGC803 gastric cancer cell line by integrating 3D-QSAR, ADMET, network pharmacology, docking, MD simulations and biological efficacy

Fouad Khalil, Abdellah El Aissouq, Lhoucine Naanaai, Hicham Zaitan, Youssra Ech-Chahdi, Yassine El Allouche
article en

Abstract

Abstract The MGC803 cell line is a human gastric cancer model frequently used in cancer research. In this context, a combined in silico approach including 3D-QSAR modeling, ADMET analysis, network pharmacology, docking, molecular dynamics and ligand transport evaluations, was applied to design new antiproliferative molecules. A robust 3D-QSAR model with high predictive capacity ( R² and Q² ) was developed and used to design new compounds (PR1–PR4). After an ADMET screening, the putative biological targets of the non-toxic compounds were predicted using PharmMapper. A network pharmacology analysis identified several hub genes, of which HSP90AA1 had the highest degree value. Given its central role in stabilizing multiple oncogenic proteins involved in gastric cancer progression, as well as its suitability for structure-based studies, HSP90AA1 was selected for molecular docking and molecular dynamics simulations. In addition, molecular docking was performed on HSP90AA1 protein (1YET) in complex with the designed molecules (PR1-PR4), and their predicted binding behaviors were compared to both the most active molecule (M34) and the reference drug, geldanamycin. These results demonstrate a high predicted binding affinity and remarkable interaction profiles within the active site of the HSP90AA1. To further evaluate the dynamic stability of these complexes, we performed molecular dynamics simulations over a 100 ns period, thus confirming stable attachment modes and durable contact networks. The MM-PBSA approach demonstrated favorable binding free energies between the chosen PR4 ligand and the 1YET protein (-26.47 ± 2.89 kcal/mol). Finally, the ligand transport study showed that the PR4 ligand easily crosses tunnels 1 and 2 with optimal theoretical transport dynamics compared to the reference drug, geldanamycin (GA). This comprehensive computational method underlines the diverse potential of the examined molecules, identifying the most promising candidates for subsequent experimental validation against gastric cancer.

Beni-Suef University Journal of Basic and Applied SciencesVol. 15(1)
Sidi Mohamed Ben Abdellah University (MA)
Openalex Percentile: Top 9%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.